- Home
- SNGX vs HRYU Comparison
SNGX vs HRYU Comparison
Compare SNGX & HRYU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SNGX
- HRYU
- Stock Information
- Founded
- SNGX 1987
- HRYU 2018
- Country
- SNGX United States
- HRYU South Korea
- Employees
- SNGX N/A
- HRYU N/A
- Industry
- SNGX Biotechnology: Pharmaceutical Preparations
- HRYU Computer Software: Programming Data Processing
- Sector
- SNGX Health Care
- HRYU Technology
- Exchange
- SNGX Nasdaq
- HRYU Nasdaq
- Market Cap
- SNGX 9.6M
- HRYU 10.5M
- IPO Year
- SNGX 1987
- HRYU 2023
- Fundamental
- Price
- SNGX $3.51
- HRYU $0.24
- Analyst Decision
- SNGX
- HRYU
- Analyst Count
- SNGX 0
- HRYU 0
- Target Price
- SNGX N/A
- HRYU N/A
- AVG Volume (30 Days)
- SNGX 56.4K
- HRYU 10.6M
- Earning Date
- SNGX 11-08-2024
- HRYU 11-26-2024
- Dividend Yield
- SNGX N/A
- HRYU N/A
- EPS Growth
- SNGX N/A
- HRYU N/A
- EPS
- SNGX N/A
- HRYU N/A
- Revenue
- SNGX $364,183.00
- HRYU $528,595.00
- Revenue This Year
- SNGX N/A
- HRYU N/A
- Revenue Next Year
- SNGX $76.64
- HRYU N/A
- P/E Ratio
- SNGX N/A
- HRYU N/A
- Revenue Growth
- SNGX N/A
- HRYU N/A
- 52 Week Low
- SNGX $1.83
- HRYU $0.17
- 52 Week High
- SNGX $32.00
- HRYU $1.50
- Technical
- Relative Strength Index (RSI)
- SNGX 49.14
- HRYU 49.58
- Support Level
- SNGX $3.50
- HRYU $0.21
- Resistance Level
- SNGX $3.74
- HRYU $0.25
- Average True Range (ATR)
- SNGX 0.20
- HRYU 0.05
- MACD
- SNGX 0.01
- HRYU -0.00
- Stochastic Oscillator
- SNGX 47.37
- HRYU 23.62
About SNGX Soligenix Inc.
Soligenix Inc is a late-stage biopharmaceutical company based in the United States. It focuses on developing and commercializing products to treat rare diseases where there is an unmet medical need. The company operates through two business segments namely Specialized BioTherapeutics and Public Health Solutions. It generates maximum revenue from Public Health Solutions with active development programs for RiVax, its ricin toxin vaccine candidate, SGX943, its therapeutic candidate for antibiotic resistant and emerging infectious disease, and its research programs to identify and develop novel vaccine candidates targeting viral infection including Ebola, Marburg and SARS-CoV-2 (the cause of COVID-19).
About HRYU Hanryu Holdings Inc.
Hanryu Holdings Inc is the creator of the engaging social media platform, FANTOO. Through FANTOO, it provides a multi-media platform for its users to interact with other like-minded users, share their appreciation of various types of entertainment and cultures, create their content, enjoy content, and engage in commerce.